BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25757683)

  • 1. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
    Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
    Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
    Kruck S; Bedke J; Kuczyk MA; Merseburger AS
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
    Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for renal cell cancer: current perspectives.
    van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
    Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
    Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
    Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
    Haas NB; Appleman LJ; Stein M; Redlinger M; Wilks M; Xu X; Onorati A; Kalavacharla A; Kim T; Zhen CJ; Kadri S; Segal JP; Gimotty PA; Davis LE; Amaravadi RK
    Clin Cancer Res; 2019 Apr; 25(7):2080-2087. PubMed ID: 30635337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
    Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
    Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
    Roulin D; Demartines N; Dormond O
    Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.